Stemrim Inc. (4599) Press Release
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
Earlier from Stemrim
- StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
- Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]